Mortality by race/ethnicity stratified by treatment
| Race . | No. (%) of patients . | Median follow-up, mo . | No. (%) of deaths . | HR (95% CI) ISS adjusted . | P . |
|---|---|---|---|---|---|
| FIRST | |||||
| White | 1340 (83) | 49 | 593 (44) | Ref | |
| Asian | 129 (8) | 39 | 50 (39) | 1.15 | .34 |
| Other | 154 (9) | 47 | 54 (35) | 0.81 | .14 |
| 403EA403 (ECOG) | |||||
| White | 377 (85) | 30 | 93 (25) | Ref | |
| Asian | 3 (1) | 25 | 0 (0) | NA | NA |
| Other | 65 (15) | 32 | 9(14) | 0.44 | .03 |
| VISTA* | |||||
| White | 302 (99) | 62 | 158 (52) | Ref | |
| Asian | 0 | NA | |||
| Other | 3 (1) | 63 | 2 (67) | 1.57 | .53 |
| S0232 (SWOG) | |||||
| White | 77 (77) | 33 | 16 (21) | Ref | |
| Asian | 1 (1) | 35 | 1 (100) | 3.3 | .25 |
| Other | 22 (22) | 30 | 4(18) | 0.80 | .68 |
| MMY3002* | |||||
| White | 304 (88) | 60 | 154 (51) | Ref | |
| Asian | 34 (10) | 56 | 20 (59) | 1.18 | .52 |
| Other | 6 (2) | 62 | 2 (33) | 1.09 | .91 |
| Meta-analysis 1† | |||||
| White | 2400 (85) | 49 | 1014 (42) | Ref | |
| Asian | 167 (6) | 40 | 71 (43) | 1.15 (0.90-1.47)‡; 1.03 (0.81-1.32)§ | .28‡; .80§ |
| Other | 250 (9) | 40 | 71 (28) | 0.76 (0.60-0.97)‡; 0.78 (0.62-0.1.00)§ | .03‡; .05§ |
| Meta-analysis 2|| | |||||
| White | 2021 (84) | 47 | 840 (42) | Ref | |
| Asian | 166 (7) | 40 | 70 (42) | 1.14 (0.89-1.46)‡; 1.02 (0.80-1.31)§ | .31‡; .87§ |
| Other | 225 (9) | 42 | 65 (29) | 0.75 (0.58-0.97)‡; 0.77 (0.59-0.99)§ | .03‡; .04§ |
| Meta-analysis 3¶ | |||||
| White | 1794 (83) | 44 | 702 (39) | Ref | |
| Asian | 133 (6) | 39 | 51 (38) | 1.14 (0.86-1.52)‡; 1.02 (0.76-1.36)§ | .37‡; .90§ |
| Other | 241 (111) | 40 | 67 (28) | 0.74 (0.58-0.96)‡; 0.77 (0.60-0.99)§ | .02‡; .04§ |
| Race . | No. (%) of patients . | Median follow-up, mo . | No. (%) of deaths . | HR (95% CI) ISS adjusted . | P . |
|---|---|---|---|---|---|
| FIRST | |||||
| White | 1340 (83) | 49 | 593 (44) | Ref | |
| Asian | 129 (8) | 39 | 50 (39) | 1.15 | .34 |
| Other | 154 (9) | 47 | 54 (35) | 0.81 | .14 |
| 403EA403 (ECOG) | |||||
| White | 377 (85) | 30 | 93 (25) | Ref | |
| Asian | 3 (1) | 25 | 0 (0) | NA | NA |
| Other | 65 (15) | 32 | 9(14) | 0.44 | .03 |
| VISTA* | |||||
| White | 302 (99) | 62 | 158 (52) | Ref | |
| Asian | 0 | NA | |||
| Other | 3 (1) | 63 | 2 (67) | 1.57 | .53 |
| S0232 (SWOG) | |||||
| White | 77 (77) | 33 | 16 (21) | Ref | |
| Asian | 1 (1) | 35 | 1 (100) | 3.3 | .25 |
| Other | 22 (22) | 30 | 4(18) | 0.80 | .68 |
| MMY3002* | |||||
| White | 304 (88) | 60 | 154 (51) | Ref | |
| Asian | 34 (10) | 56 | 20 (59) | 1.18 | .52 |
| Other | 6 (2) | 62 | 2 (33) | 1.09 | .91 |
| Meta-analysis 1† | |||||
| White | 2400 (85) | 49 | 1014 (42) | Ref | |
| Asian | 167 (6) | 40 | 71 (43) | 1.15 (0.90-1.47)‡; 1.03 (0.81-1.32)§ | .28‡; .80§ |
| Other | 250 (9) | 40 | 71 (28) | 0.76 (0.60-0.97)‡; 0.78 (0.62-0.1.00)§ | .03‡; .05§ |
| Meta-analysis 2|| | |||||
| White | 2021 (84) | 47 | 840 (42) | Ref | |
| Asian | 166 (7) | 40 | 70 (42) | 1.14 (0.89-1.46)‡; 1.02 (0.80-1.31)§ | .31‡; .87§ |
| Other | 225 (9) | 42 | 65 (29) | 0.75 (0.58-0.97)‡; 0.77 (0.59-0.99)§ | .03‡; .04§ |
| Meta-analysis 3¶ | |||||
| White | 1794 (83) | 44 | 702 (39) | Ref | |
| Asian | 133 (6) | 39 | 51 (38) | 1.14 (0.86-1.52)‡; 1.02 (0.76-1.36)§ | .37‡; .90§ |
| Other | 241 (111) | 40 | 67 (28) | 0.74 (0.58-0.96)‡; 0.77 (0.60-0.99)§ | .02‡; .04§ |
CI, confidence interval; FIRST, Frontline Investigation of Revlimid + Dexamethasone Versus Standard Thalidomide; ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System; NA, not available; Ref, referent; SWOG, Southwest Oncology Group; VISTA, V-domain Immunoglobulin Suppressor of T-cell Activation.
Ethnicity was not included as a variable for these studies, although race was listed as Hispanic for 1 patient in each of these studies.
Cox model stratified by study and treatment.
Stratified by study and treatment.
Stratified by ISS stage, study, and treatment.
Cox model stratified by study and treatment, excluding VISTA and S0232.
Cox model stratified by study and treatment, excluding VISTA and MMY3002.